• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Adverum Biotechnologies Inc.

    5/28/24 2:00:14 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADVM alert in real time by email
    DEFA14A 1 ef20030013_defa14a.htm DEFA14A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 14A INFORMATION
     
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No. )

    Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐

    Check the appropriate box:
    ☐
    Preliminary Proxy Statement
    ☐
    Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2))
    ☐
    Definitive Proxy Statement
    ☒
    Definitive Additional Materials
    ☐
    Soliciting Material Under Rule 14a-12

    Adverum Biotechnologies, Inc.
    (Name of Registrant as Specified in its Charter)
     
    Payment of Filing Fee (Check all boxes that apply):
    ☒
    No fee required
    ☐
    Fee paid previously with preliminary materials.
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



    This proxy supplement, dated May 28, 2024 (this “Supplement”), supplements the definitive proxy statement on Schedule 14A of Adverum Biotechnologies, Inc. a Delaware corporation (the “Company”), filed with the Securities and Exchange Commission on May 2, 2024 (the “Proxy Statement”), for the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company to be held on Monday, June 17, 2024. Capitalized terms used in this Supplement and not otherwise defined herein have the meanings given to them in the Proxy Statement.

    Amendment and Restatement of Non-Employee Director Compensation Policy

    The Company maintains a non-employee director compensation policy. In May 2024, the compensation committee of the Company’s board of directors approved the amendment and restatement of the Company’s non-employee director compensation policy. The non-employee director compensation policy as amended and restated on May 22, 2024, is set forth below.
     
    Adverum Biotechnologies, Inc.
     
    Non-Employee Director Compensation Policy Adopted by

    the Compensation Committee: May 22, 2024

    Each member of the board of directors (the “Board”) of Adverum Biotechnologies, Inc. (the “Company”) who is a Non-Employee Director (as defined in the Adverum Biotechnologies, Inc. 2024 Equity Incentive Award Plan (the “Plan”) will be eligible to receive cash and equity compensation as set forth in this Adverum Biotechnologies, Inc. Non-Employee Director Compensation Policy (this “Policy”). For the purposes of this Policy, “Total Direct Annual Compensation” shall mean the aggregate amount of cash and equity compensation to which a Non-Employee Director is entitled pursuant to this Policy, other than any such compensation received for service as Chair of the Board. Capitalized terms not explicitly defined in this Policy but defined in the Plan will have the same definitions as in the Plan.
     
    This Policy, as adopted on May 22, 2024, will become effective immediately and will remain in effect until it is revised or rescinded by further action of the Board or the Compensation Committee of the Board; provided, however, that the Compensation Limits (as defined in Section 1 below), which, for the avoidance of doubt, supersede any non-employee director compensation limits set forth in the Plan, shall apply for a period of three years.
     
    1.
    Total Direct Annual Compensation Limits
     
    The limits below (each a “Compensation Limit”) shall apply to the Total Direct Annual Compensation granted to each Non-Employee Director, other than a new Non-Employee Director. In applying the Compensation Limits below, the calculation of the Company’s market capitalization shall be made as of the date of the equity compensation grant.

     
    a.
    While the Company’s market capitalization is below $250 million, Total Direct Annual Compensation shall not exceed $150,000 in any calendar year.
     

    b.
    While the Company’s market capitalization is greater than $250 million but below $500 million, Total Direct Annual Compensation shall not exceed $250,000 in any calendar year.
     

    c.
    While the Company’s market capitalization is greater than $500 million but below $1 billion, Total Direct Annual Compensation shall not exceed $400,000 in any calendar year.
     

    d.
    While the Company’s market capitalization is higher than $1 billion, Total Direct Annual Compensation shall not exceed $475,000 in any calendar year.


    2.
    Cash Compensation.
     
    (a)         Annual Retainers. Each Non-Employee Director will be eligible to receive the following annual retainers for service as (i) a member and/or chair of the Board and (ii) a member or chair/co-chair of a committee of the Board (“Committee”) set forth below, as applicable.
     
    Board or Committee
    Type of Retainer*
     
    Amount (Per Year)
     
    Board
    Chair
     
    $35,000
     
    Member
     
    $40,000
     
    Audit Committee
    Chair
     
    $20,000
     
    Member (Non- Chair)
     
    $10,000
     
    Compensation Committee
    Chair
     
    $15,000
     
    Member (Non- Chair)
     
    $7,500
     
    Nominating and Corporate Governance Committee
    Chair
     
    $10,000
     
    Member (Non- Chair)
     
    $5,000
     
    Research and Development Committee
    Chair/Co-Chair
     
    $15,000
     
    Member (Non- Chair/Co-Chair)
     
    $7,500
     
     
    *
    The chair of the Board is eligible to receive a retainer for service as the chair and an additional retainer for service as a member of the Board. The chair/co-chair of each Committee is eligible to receive a retainer for service as the chair/co-chair, but not an additional retainer for service as a member of the Committee.
     
    The annual retainers will be paid on the last day of the quarter and partial service for that quarter will receive pro rata treatment.
     
    (b)    Expenses. Each Non-Employee Director will be eligible for reimbursement from the Company for all reasonable out-of-pocket expenses incurred by the Non-Employee Director in connection with his or her attendance at Board and Committee meetings.
     
    To the extent that any taxable reimbursements are provided to a Non-Employee Director, they will be provided in accordance with Section 409A of the Internal Revenue Code of 1986, as amended, and the Treasury Regulations and other guidance thereunder and any state law of similar effect, including, but not limited to, the following provisions: (i) the amount of any such expenses eligible for reimbursement during the Non-Employee Director’s taxable year may not affect the expenses eligible for reimbursement in any other taxable year; (ii) the reimbursement of an eligible expense must be made no later than the last day of the Non-Employee Director’s taxable year that immediately follows the taxable year in which the expense was incurred; and (iii) the right to any reimbursement may not be subject to liquidation or exchange for another benefit.


    3.
    Equity Compensation.
     
    The options described in this Policy will be granted under the Plan and will be subject to the terms and conditions of (i) this Policy, (ii) the Plan and (iii) the form of Option Agreement approved by the Board for the grant of options to Non-Employee Directors under the Plan.
     
    (a)         Initial Grants. Each person who first becomes a Non-Employee Director, whether through election by the stockholders of the Company or appointment by the Board to fill a vacancy, will be granted a Nonstatutory Stock Option to purchase a number of shares of Common Stock having an Option Value of 200% of the Option Value of the most recent Annual Director Option granted pursuant to Section 3(b)(i) below (an “Initial Option”), which grant will be made on or about the date of his or her initial election or appointment to be a Non-Employee Director.
     
    (b)          Annual Grants. On or about the date of each annual meeting of the Company’s stockholders:
     
    (i)          each person who is then a Non-Employee Director and will be continuing as a Non- Employee Director following the date of such annual meeting (other than any Non-Employee Director receiving an Initial Option on the date of such annual meeting or who has received an Initial Option within the same calendar year as such annual meeting) will be granted a Nonstatutory Stock Option to purchase a number of shares of Common Stock having an Option Value represented by the number of shares approximately equal to the median annual equity award (as a percent of company) granted to non-employee directors of the Company’s Peer Group (as defined in the charter of the Compensation Committee of the Board) as applied to the number of shares of the Company’s stock outstanding as of the date of grant (provided that such Option Value should not exceed the applicable Compensation Limit minus the maximum annual cash compensation (excluding, if applicable, the Board Chair retainer) to which any director is expected to be entitled during the calendar year pursuant to Section 2(a) above) (an “Annual Director Option”); and
     
    (ii)        the Chair of the Board will be granted an additional Nonstatutory Stock Option to purchase a number of shares of Common Stock having an Option Value equal to approximately 30% of the Option Value of the Annual Director Option (the “Annual Chair Option”).
     
    (c)         Option Value. The “Option Value” of a stock option to be granted under this policy will be determined using the same method the Company uses to calculate the grant date fair value of stock options in its financial statements and shall be calculated on the date of grant.
     
    (d)          Terms of Options.
     
    (i)          Exercise Price. The exercise price of each Initial Option, Annual Director Option and Annual Chair Option will be equal to 100% of the Fair Market Value of the Common Stock subject to such option (as determined in accordance with the Plan) on the date such option is granted.
     
    (ii)         Vesting.  Each Initial Option, Annual Director Option and Annual Chair Option will vest and become exercisable as follows:
     
    (A)          Each Initial Option will vest and become exercisable in equal annual installments on each of the first three anniversaries of the date of grant of such option, provided that the Non-Employee Director has not had a Termination of Service prior to each such date; provided, however, that the vesting shall accelerate, and the Initial Option shall become fully vested and exercisable, upon the consummation of a Change in Control.


    (B)          Each Annual Director Option and Annual Chair Option will vest and become exercisable on the earlier of (i) the date of the next annual meeting of the Company’s stockholders, or (ii) the first anniversary of the date of grant of such option, provided that the Non-Employee Director has not had a Termination of Service prior to such date; provided, however, that the vesting shall accelerate, and each Annual Option shall become fully vested and exercisable, upon the consummation of a Change in Control.

    THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT. EXCEPT AS SPECIFICALLY SUPPLEMENTED BY THE INFORMATION CONTAINED HEREIN, THIS SUPPLEMENT DOES NOT MODIFY ANY OTHER INFORMATION SET FORTH IN THE PROXY STATEMENT.



    Get the next $ADVM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADVM

    DatePrice TargetRatingAnalyst
    11/17/2025Buy → Neutral
    H.C. Wainwright
    6/25/2024$25.00Outperform
    Oppenheimer
    4/30/2024$30.00Buy
    H.C. Wainwright
    7/7/2022$4.00Hold → Buy
    Truist
    7/23/2021Hold → Neutral
    Cantor Fitzgerald
    7/23/2021$23.00 → $3.00Overweight → Neutral
    Cantor Fitzgerald
    7/23/2021$5.00 → $2.00Market Perform
    SVB Leerink
    More analyst ratings

    $ADVM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

    INDIANAPOLIS, Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY)  and Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the tender offer (the "Offer") by Flying Tigers Acquisition Corporation ("Purchaser"), a direct wholly-owned subsidiary of Lilly, to purchase all of the issued and outstanding shares ("Shares") of Adverum's common stock in exchange for (i) $3.56 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the st

    12/9/25 8:28:00 AM ET
    $ADVM
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly

    REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And DoneTM treatment to preserve sight for life, today announced that it has mailed a letter to its stockholders in connection with its pending transaction to be acquired by Eli Lilly and Company ("Lilly"). In accordance with the merger agreement between Lilly and Adverum, on November 7, 2025 Lilly commenced a tender offer to acquire all of the outstanding shares of Adverum's common stock for a per share price of (1) $3.56 per share in cash payable at closing plus (2) one non-transferable contingent

    12/1/25 7:00:00 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lilly to Acquire Adverum Biotechnologies

    Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve

    10/24/25 8:30:00 AM ET
    $ADVM
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ADVM
    SEC Filings

    View All

    SEC Form 15-12G filed by Adverum Biotechnologies Inc.

    15-12G - Adverum Biotechnologies, Inc. (0001501756) (Filer)

    12/19/25 4:00:16 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Adverum Biotechnologies Inc.

    EFFECT - Adverum Biotechnologies, Inc. (0001501756) (Filer)

    12/12/25 12:15:05 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Adverum Biotechnologies Inc.

    EFFECT - Adverum Biotechnologies, Inc. (0001501756) (Filer)

    12/12/25 12:15:03 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, PRESIDENT AND DIRECTOR Fischer Laurent bought $553,917 worth of shares (128,699 units at $4.30), increasing direct ownership by 177% to 201,513 units (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/8/25 9:45:06 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF OPERATING OFFICER Soparkar Peter bought $211,000 worth of shares (50,000 units at $4.22), increasing direct ownership by 166% to 80,189 units (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/8/25 9:45:04 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

    4/A - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    4/28/25 3:31:52 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, PRESIDENT AND DIRECTOR Fischer Laurent exercised 150,000 shares at a strike of $4.20 and was granted 500,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/10/25 1:52:31 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF OPERATING OFFICER Soparkar Peter was granted 150,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/10/25 1:49:41 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Ozden Rabia Gurses was granted 85,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/10/25 1:46:33 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Adverum Biotech downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Adverum Biotech from Buy to Neutral

    11/17/25 9:39:07 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Adverum Biotech with a new price target

    Oppenheimer initiated coverage of Adverum Biotech with a rating of Outperform and set a new price target of $25.00

    6/25/24 8:10:21 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Adverum Biotech with a new price target

    H.C. Wainwright initiated coverage of Adverum Biotech with a rating of Buy and set a new price target of $30.00

    4/30/24 6:15:49 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to Acquire Adverum Biotechnologies

    Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve

    10/24/25 8:30:00 AM ET
    $ADVM
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

    - 52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial officer - On track to initiate pivotal program in 1H 2025 - $153.2 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter of 2024 and provided updates to anticipated milestones. "We remain laser focused on initiating

    11/4/24 4:39:45 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

    REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of Jason L. Mitchell as chief commercial officer. Mr Mitchell brings to Adverum over 20 years of commercial experience, including in retinal disease, and most recently oversaw the successful launch of SYFOVRE® in geographic atrophy (GA). In his new role, Mr. Mitchell will be responsible for setting the launch strategy and building the commercial infrastructure for ixoberogene soroparvovec (Ixo-vec), Adverum's potential one-time intravitreal (IVT) injec

    10/16/24 8:00:00 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

    SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

    11/14/24 6:57:12 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

    SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

    11/14/24 6:40:56 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

    SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

    11/14/24 4:05:12 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    Financials

    Live finance-specific insights

    View All

    Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

    REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) being presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The webcast will be held on Wednesday, July 17 at 8:00 a.m. ET and will include a presentation from Dr. Charles C. Wykoff, Director of Res

    7/10/24 8:00:00 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

    - Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET - REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related

    2/1/24 5:30:00 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

    REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024. "We are very pleased to have the opportunity to present our initial Phase 2 efficacy and safety data from the LUNA study at the Macula Society meeting" stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. "We recently received confirmation that ou

    12/7/23 4:05:00 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care